Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. Clin Cancer Res. 2019 02 15; 25(4):1174-1184.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Aged, 80 and over
B-Lymphocytes
Dose-Response Relationship, Drug
Female
Humans
Janus Kinases
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Male
Middle Aged
Protein Kinase Inhibitors
Pyrimidines
Receptors, Antigen, B-Cell
Signal Transduction
Sulfones
Syk Kinase
Tumor Microenvironment

authors with profiles

Jeremy Segal